Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03290885
Other study ID # 2017014F
Secondary ID 2016-A01735-46
Status Completed
Phase N/A
First received
Last updated
Start date October 16, 2017
Est. completion date February 28, 2020

Study information

Verified date May 2020
Source Hopital Foch
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mechanical thrombectomy (MT) with a stent retriever (SR) device is now the standard intervention in ischemic stroke with large vessel occlusion. Favorable outcome is strongly associated with the successful reperfusion status. New device of MT such as contact aspiration seems promising to increase reperfusion status and clinical outcome.

The main hypothesis is to show the superiority of combining the use of contact aspiration with a stent retriever compared to a stent retriever alone in treatment of acute stroke due to proximal arterial occlusion.

The primary endpoint is the rate of perfect reperfusion score at the end of the endovascular procedure.


Recruitment information / eligibility

Status Completed
Enrollment 408
Est. completion date February 28, 2020
Est. primary completion date February 28, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age 18 and older (i.e., candidates must have had their 18th birthday)

- Groin puncture carried out within 8 hours of first symptoms

- Neuroimaging demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation, M1 or M2)

- Consenting requirements met according to French laws.

- With or without intravenous thrombolysis

Exclusion Criteria:

- Absence of large vessel occlusion on non-invasive imaging

- Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory

- Suspected pregnancy; if, a woman is of childbearing potential, a urine or serum beta human chorionic gonadotropin (betaHCG) test is positive.

- Severe contrast medium allergy or absolute contraindication to iodinated agents.

- Patient has severe or fatal comorbidities that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.

- Acute ischemic stroke involving posterior circulation (vertebrobasilar occlusion)

- Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment.

- Patients benefiting from a legal protection

- Non-membership of a national insurance scheme

- Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Combined contact aspiration/Stent Retriever Technique
Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
Device:
Stent retriever technique
The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA. A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion. After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter.

Locations

Country Name City State
France CHU Bordeaux Bordeaux
France CHU Limoges Limoges
France CHU Montpellier Montpellier
France CHU Nancy Nancy
France CHU Nantes Nantes
France Fondation Ophtalmologique Rotschild Paris
France Kremlin-Bicêtre (APHP) Paris
France La Pitié-Salpétrière (APHP) Paris
France Lariboisière (APHP) Paris
France CHU Rennes Rennes
France Hôpital Foch Suresnes

Sponsors (1)

Lead Sponsor Collaborator
Hopital Foch

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Perfect reperfusion rate Perfect reperfusion rate at the end of angiography defined as a Thrombolysis In Cerebral Infarction (TICI) 2c/3 score (TICI score = Thrombolysis In Cerebral Infarction) 24 hours
Secondary Rate of successful reperfusion Rate of successful reperfusion (mTICI 2b/2c/3), and complete reperfusion (mTICI3) at end of endovascular procedure 24 hours
Secondary Rate of perfect (mTICI 2c/3), successful reperfusion (mTICI 2b/2c/3), and complete reperfusion (mTICI3) after the frontline strategy 24 hours
Secondary Time from groin puncture to achieve TICI 2c or better revascularization Time from groin puncture to achieve TICI 2c or better revascularization 24 hours
Secondary Time between groin puncture to clot contact and clot contact to maximum reperfusion Time between groin puncture to clot contact and clot contact to maximum reperfusion 24 hours
Secondary Modified Rankin scale (mRs) Global disability assessed by overall distribution of mRs at 90-days 90 days
Secondary Rate of favorable functional independence Rate of favorable functional independence defined as a mRS 0-2 at 90 days 90 days
Secondary Rate of excellent functional outcome Rate of excellent functional outcome defined as a Modified Rankin scale (mRS) 0-1 at 90 days 90 days
Secondary NIHSS score Change in NIHSS from baseline to 24 hours (delta NIHSS) 24 hours
Secondary Rate of symptomatic and asymptomatic intracerebral hemorrhage Rate of symptomatic and asymptomatic intracerebral hemorrhage at MRI 24h after thrombectomy (according the third European Cooperative Acute Stroke Study (ECASS3) classification) (independent core lab adjudication). 24 hours
Secondary Rate of parenchymal hematoma 90 days
Secondary Rate of all-cause mortality 90 days
Secondary Rate of periprocedural complications - Rate of periprocedural complications: Occurrence of emboli to new territory (ENT), vasospasm, dissection, or perforation. 90 days
Secondary Average cost per patient Average cost per patient with complete recanalization 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3